The Danish pharmaceutical giant is navigating one of its most consequential stretches in years, juggling a clinical setback, a courtroom victory, and a strategic recalibration of its blockbuster obesity franchise. The picture that emerges is of a company hedging its bets across multiple fronts — sometimes in ways that appear contradictory on the surface.
A Clinical Miss That Won’t Move the Needle — Financially
Late July brought unwelcome news from the lab. The Phase 3 ZEUS trial evaluating ziltivekimab, an antibody targeting the inflammatory marker IL-6, failed to meet its primary endpoint. Among patients with atherosclerotic cardiovascular disease, chronic kidney disease, and elevated inflammation, the drug did not significantly reduce the risk of major adverse cardiovascular events versus placebo. The hazard ratio landed at 0.99 — effectively no difference from the control group.
Novo Nordisk will book a non-cash impairment charge in the third quarter as a result, though management insists the previously communicated 2026 profit guidance remains intact. Two other trials with the same compound — HERMES, studying heart failure, and ARTEMIS, examining post-heart-attack patients — are still running, with readouts expected in the first half of 2027. For now, that part of the pipeline remains in limbo.
A Legal Victory in The Hague
On the legal front, the company secured a more favorable outcome. A district court in The Hague issued a preliminary injunction against Dutch compounding pharmacy Ceban Ziekenhuisfarmacie B.V., barring the sale of a compounded semaglutide nasal spray. The court found the product infringed Novo Nordisk’s supplementary protection certificate for semaglutide, ordering Ceban to remove product listings, disclose supply chain information, and cover the company’s legal costs.
The ruling carries a notable wrinkle: no regulatory authority worldwide has approved a nasal spray formulation of semaglutide. The decision underscores the company’s willingness to defend its intellectual property aggressively as compounded GLP-1 products proliferate.
The Buyback Machine Keeps Humming
On the capital returns front, the ongoing share repurchase program — authorized for up to 15 billion Danish kroner — continues apace. Since the program’s launch on February 4, Novo Nordisk has bought back roughly 28.9 million B-shares at an average price of 279.80 Danish kroner, representing a total outlay of about 8.08 billion kroner.
The buyback signals management’s conviction that the stock is undervalued. Yet it also raises a question the company can’t answer with share repurchases alone: can the pipeline deliver? Notably, media reports indicate that executives have predominantly sold shares over the past 90 days, with no offsetting insider purchases — a pattern observers are tracking, even if the scale doesn’t carry immediate market implications.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Smaller Doses, Bigger Ambitions
The more intriguing development came on August 12, when Novo Nordisk initiated OASIS-5, a late-stage trial testing lower strengths of the Wegovy pill. The study, which runs through 2028, aims to identify the lowest effective maintenance dose.
This is not a minor tweak. In a market where tolerability and long-term adherence often determine commercial success, a well-calibrated minimum dose could be the difference between a blockbuster and a drug patients abandon after a few months. The strategy reflects a broader bet: rather than chasing the strongest efficacy numbers, Novo Nordisk appears to be competing on the full package — side-effect profile, market access, and brand trust.
CEO Mike Doustdar articulated this approach in mid-August, arguing that investors underestimate demand for differentiated obesity medications. He confirmed plans to bring CagriSema to market next year, despite the candidate having trailed Eli Lilly’s Zepbound on weight loss in clinical trials.
Diabetes: The Quiet Second Engine
While obesity dominates headlines, the company is also pressing forward in its historical home turf. Early August saw the U.S. launch of Awiqli, which Novo Nordisk describes as the first once-weekly basal insulin for adults with type 2 diabetes, following FDA approval. The product addresses the same compliance dynamic central to the obesity pill strategy: less frequent administration, better adherence.
The company’s partnership with Amazon Web Services, formalized in early August, adds a technological layer to the story. A joint innovation hub in London will bring together engineers and scientists from both companies to compress the timeline from target identification to first human application. Novo Nordisk reports measurable early gains, including reduced documentation time in clinical trials, with more than 25,000 employees expected to benefit from the new tools.
What the Market Makes of It
The stock closed Friday at 39.98 euros, up 1.0 percent on the day and 1.6 percent for the week. The short-term bounce masks a tougher stretch: the shares are down 5.1 percent over the past 30 days and 9.2 percent year-to-date. At 27 percent below the 52-week high of 54.86 euros reached in January, investor confidence remains tentative.
The next major catalyst arrives on November 4, when Novo Nordisk reports third-quarter results. By then, the market will have had time to digest whether the company’s multi-pronged strategy — defending its intellectual property, returning capital, and fine-tuning its most important product — is gaining traction. The pipeline decisions of the coming months, not the buyback program, will ultimately provide the answer.
Ad
Novo Nordisk Stock: Buy or Sell?! New Novo Nordisk Analysis from August 23 delivers the answer:
The latest Novo Nordisk figures speak for themselves: Urgent action needed for Novo Nordisk investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from August 23.
Novo Nordisk: Buy or sell? Read more here...
